Mesangial cell hypercellularity and iron accumulation in the kidney associated with administration of a sickle

Shambhunath Choudhary1, Catherine Picut2, Sarah R Vargas3

  • 1Pfizer Inc., Pearl River, NY.

Veterinary Pathology
|December 23, 2024
PubMed

Insights

Sickle hemoglobin modulators increase red blood cell turnover, leading to iron overload in kidneys. This causes mesangial cell proliferation and inflammation, highlighting potential renal toxicity in sickle cell disease treatment.

Area of Science:

  • Nephrology
  • Hematology
  • Toxicology

Background:

  • The kidney is crucial for iron homeostasis.
  • Mesangial cells (MCs) are vital for glomerular homeostasis.
  • Sickle hemoglobin (HbS) modulators are investigated for sickle cell disease (SCD).

Purpose of the Study:

  • To investigate the renal effects of HbS modulators in a preclinical model.
  • To understand the role of iron metabolism in HbS modulator-induced kidney changes.

Main Methods:

  • CD-1 mice were treated with an HbS modulator for up to 26 weeks.
  • Kidney tissues were analyzed for pigment deposition, MC changes, and inflammation.
  • Perl's iron staining and transmission electron microscopy (TEM) were used for pigment identification.
  • Ki-67 immunolabeling assessed MC proliferation.

Main Results:

  • HbS modulator treatment led to increased red blood cell (RBC) mass and turnover.
  • Iron-containing pigment deposition was observed in renal tubules and MCs.
  • MC hypercellularity and tubulo-interstitial inflammation were noted with long-term treatment.
  • Findings suggest iron overload secondary to increased RBC turnover causes renal iron reabsorption.

Conclusions:

  • HbS modulators can induce kidney iron accumulation and mesangial cell hypercellularity.
  • MC hypercellularity may represent a homeostatic response to iron overload.
  • Tubulo-interstitial inflammation suggests iron-catalyzed oxidative stress.
  • This study is the first to report MC hypercellularity in a preclinical toxicity study of HbS modulators.